Japanese Scientists Just Announced a Drug That Regrows Human Teeth. The Ingredient It's Built On Has Been in Toothpaste Since 1980.

For most of human history, losing a tooth meant losing it forever.

Sharks regrow teeth. Crocodiles regrow teeth. Most fish regrow teeth. Humans — uniquely among vertebrates — get exactly two sets and nothing more. The scientific assumption, for most of the 20th century, was that this was simply fixed biology. Non-negotiable.

That assumption is now being formally challenged by a research team in Kyoto, Japan.

In 2024, scientists at Kyoto University Hospital announced that a drug they've been developing — targeting a protein called USAG-1 that suppresses tooth growth — had shown the ability to stimulate new tooth formation in animal trials. Human clinical trials are now underway. If the results hold, it will be the first drug in history capable of regrowing a lost human tooth.

The headlines focused on the drug. But the researchers who've been following this field for years focused on something else: the underlying mechanism. Because the principle that makes this drug theoretically possible — that tooth tissue is not permanently fixed, that enamel and dentine can be reformed under the right biological conditions — is the same principle that a quiet corner of Japanese dentistry has been applying for over four decades.

You've probably never heard of it. But you can use it tonight.

What the Kyoto Research Actually Found

To understand why this discovery matters — and why it connects to something far more accessible than a clinical trial drug — you need to understand what teeth are actually made of.

Tooth enamel is the hardest substance the human body produces. It's approximately 97% mineral — specifically, a calcium phosphate crystal called hydroxyapatite. Dentine, the layer underneath enamel, is about 70% hydroxyapatite. The rest is collagen and water.

When a tooth is damaged — whether by acid erosion, bacterial attack, or physical wear — what's being destroyed is hydroxyapatite. The crystal lattice breaks down. Micro-cracks form. Pores open in the enamel surface. The tooth becomes progressively weaker and more vulnerable to decay.

The Kyoto team's breakthrough was identifying that the human body retains the biological machinery to form new dental tissue — including new hydroxyapatite crystals — but that this process is actively suppressed by the USAG-1 protein. Their drug works by blocking that suppressor. Switch off USAG-1, and the body's latent tooth-forming cells reactivate.

That last sentence is the one that changes everything.

Hydroxyapatite crystals form the scaffolding of tooth enamel. At nano-scale, they can fill micro-pores and integrate with existing tooth structure.

The 40-Year Head Start Japan Already Has

While Western dentistry was focused on fluoride — a mineral that makes enamel more resistant to acid attack but doesn't rebuild damaged enamel — Japanese researchers were asking a different question.

What if instead of making teeth harder to damage, you gave them the ability to repair themselves?

In the 1970s, NASA scientists working on bone and tooth loss in astronauts identified hydroxyapatite as a potential material for biological repair. Japanese researchers picked up this thread and spent the following decade developing a nano-scale version — particles small enough to penetrate enamel micro-pores and physically bond to existing tooth structure.

By the 1980s, nano-hydroxyapatite (nano-HAp) toothpaste was commercially available in Japan. By the 1990s, it was approved as an anti-caries agent by the Japanese Ministry of Health. Today it's in mainstream Japanese toothpastes used by tens of millions of people.

In the rest of the world? Fluoride remained the default. Not because it was better — the published research doesn't support that conclusion. But because fluoride had a 50-year head start in public health infrastructure, regulation, and industry investment. Changing the default recommendation meant challenging an enormous amount of institutional inertia.

The Kyoto tooth regeneration announcement is the moment that inertia starts shifting. Because when a university announces a drug that regrows teeth by stimulating the body's hydroxyapatite formation pathways — and that drug makes international headlines — it becomes very hard to keep telling people that hydroxyapatite is an "alternative" ingredient.

How Nano-Hydroxyapatite Actually Rebuilds Your Teeth

This is the part most articles skip. They'll tell you that hydroxyapatite "remineralises" teeth without explaining what that actually means at the structural level. Let's be precise.

When acid — from food, drink, or bacterial metabolic waste — contacts your enamel, it dissolves the outer hydroxyapatite crystals. This process is called demineralisation. It's happening constantly in your mouth, particularly after meals. Normally, your saliva partially counteracts this by providing calcium and phosphate ions that allow some remineralisation. But saliva alone can't keep up, especially in people with high-sugar diets, dry mouth, or high oral bacterial loads.

The result is a progressively porous enamel surface — microscopically pitted and weakened, invisible to the naked eye but very much present. This is the precursor stage to visible decay. The stage that dentists rarely catch because it hasn't yet progressed to a cavity.

Fluoride's mechanism is different. It converts hydroxyapatite into fluorapatite — a harder, more acid-resistant crystal. This is protective, but it's a transformation of existing tooth structure, not a repair of lost structure. Once enamel is gone, fluoride can't bring it back.

Nano-HAp can. That's the fundamental difference. And it's the difference that explains why Japanese researchers working on tooth regeneration have been using hydroxyapatite as their base material — not fluoride — for 40 years.

People who switch to nano-HAp often notice reduced sensitivity within weeks — a direct result of enamel micro-pores being physically filled.

What People Notice When They Switch

The research tells one story. The people who've actually made the switch tend to tell a more immediate one.

The Drug Is Years Away. This Isn't.

The Kyoto tooth regeneration drug is real, the science is solid, and the clinical trials are underway. If Phase 1 results hold, Phase 2 trials could begin within two years. A commercially available tooth regrowth drug — if everything goes right — is likely still a decade away from your bathroom cabinet.

Frequently Asked Questions